StockNews.AI
EPIX
StockNews.AI
175 days

Levi & Korsinsky Notifies ESSA Pharma Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - EPIX

1. Class action lawsuit launched against EPIX investors for alleged securities fraud. Investors face potential losses. 2. Allegations claim masofaniten plus enzalutamide lacks efficacy over enzalutamide alone. Clinical benefits questioned. 3. Complaint states the M-E Combination Study will likely miss its Phase 2 primary endpoint. Efficacy overstated. 4. Investors eligible for compensation until March 25, 2025. Participation incurs no cost.

4m saved
Insight
Article

FAQ

Why Bearish?

A lawsuit claiming misleading statements may erode investor confidence and depress the stock price. Similar legal challenges in biotech have led to short-term declines.

How important is it?

The lawsuit introduces significant legal risk and negative sentiment, potentially impacting stock performance. Investors may closely monitor the legal process and its outcomes.

Why Short Term?

The legal uncertainty is likely to drive near-term volatility until the case is resolved. Past cases in comparable firms support this timing.

Related Companies

EPIX
NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=131750&wire=4 EPIX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (iii) the M-E Combination Study, a monotherapy and combination therapy for the treatment of prostate cancer, was unlikely to meet its prespecified Phase 2 primary endpoint; (iv) accordingly, defendants had overstated masofaniten's clinical, regulatory, and commercial prospects; and (v) as a result, defendants' public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in ESSA Pharma Inc. during the relevant time frame, you have until March 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP

Related News